Verisfield is in compliance with the current legislation regarding the pharmacovigilance requirements set by the EMA. For this reason it has available a pharmacovigilance system for recording, monitoring and reporting to the Health Authorities possible adverse events resulting from the use of Verisfield’s products.
Moreover, in cooperation with Ibsa, Verisfield reports to Ibsa possible adverse events from the use of the product lines Aliaxin® & Viscoderm® distributed by Verisfield in Greece and Cyprus.
Contact the pharmacovigilance department (24/7) at +30 210 7475196 (ext. 6) or at email@example.com